FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086508722> ?p ?o ?g. }

• W2086508722 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CASemaphorin4D (SEMA4D) normally functions to regulate, adhesion, motility and activation state of multiple cell types including those of the nervous, vascular and immune systems. In the setting of cancer, SEMA4D has been shown to promote tumor progression and metastasis. SEMA4D and its high affinity receptor plexin B1 are broadly expressed in human and murine tumors, and expression levels correlate with invasive disease in several human tumors. The interaction of plexin B1 with MET and ERBB2 can lead to SEMA4D-mediated transactivation of these membrane receptor kinases with a direct effect on tumor cell migration and invasive growth. Moreover, SEMA4D is highly expressed by inflammatory cells that are recruited to the tumor microenvironment.Purpose: Determine the role(s) of SEMA4D in shaping the tumor microenvironment, and investigate the anti-tumor response mediated by antibody neutralization of SEMA4D as a single agent or in combination with other immunomodulatory therapies.Methods: Subcutaneous colon and orthotopic ERBB2+ breast carcinoma models were employed to investigate treatment with a monoclonal antibody to SEMA4D. Anti-tumor response and tumor infiltrating immune cell profiles were characterized by in vivo growth kinetics, immunohistochemistry, FACS, and functional assays.Results: We describe an immunomodulatory function of SEMA4D within the tumor microenvironment, whereby SEMA4D influences the recruitment and activity of cytotoxic CD8+ T cells, the density of B cells within the tumor, and regulates the balance and localization of inflammatory M1 and tolerance-inducing M2 macrophage in tumor stroma. Antibody blockade of SEMA4D modifies the balance of immune cells and production of pro-inflammatory cytokines within the tumor microenvironment, promotes tumor rejection, and induces ∼30% tumor growth delay (TGD) in Colon26 and >70% TGD in Tubo breast tumor models. Furthermore, combination of SEMA4D antibody with immune checkpoint blockade inhibitor antibodies to CTLA4 and PD1, significantly improves frequency of complete tumor rejection (58% and 37%) and increases survival (>295% and >55% TGD respectively) as compared to monotherapy with these targeted agents. Similar combinatorial effects were observed when anti-SEMA4D antibody is administered with immunomodulatory chemotherapy, such as cyclophosphamide, which increases efficacy (81% TGD) and frequency of complete rejection (40%) in tumor engrafted mice.Conclusion: SEMA4D represents a novel immunological target and antibody neutralization of SEMA4D may be a novel therapeutic option for cancer treatment. The humanized anti-SEMA4D antibody, VX15/2503, has successfully completed IND-enabling toxicology testing and the dose escalation phase of a Phase I trial, in which the highest doses were well tolerated in adult patients with advanced solid tumors.Citation Format: Elizabeth E. Evans, Holm Bussler, Sebold Torno, Janaki Veeraraghavan, Alan S. Jonason, Michael A. Doherty, Christine Reilly, Crystal Mallow, Jennifer Seils, Mark Paris, Terrence L. Fisher, William J. Bowers, Maria Scrivens, Leslie Balch, Renee Kirk, Alan Howell, Valerie Iddison, John E. Leonard, Ernest S. Smith, Maurice Zauderer. Antibody blockade of Semaphorin 4D promotes tumor rejection and improves response to immune checkpoint blockade and chemotherapy. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5030. doi:10.1158/1538-7445.AM2014-5030" @default.
• W2086508722 created "2016-06-24" @default.
• W2086508722 creator A5000194661 @default.
• W2086508722 creator A5001292309 @default.
• W2086508722 creator A5001835930 @default.
• W2086508722 creator A5009743534 @default.
• W2086508722 creator A5017065543 @default.
• W2086508722 creator A5018161067 @default.
• W2086508722 creator A5022624265 @default.
• W2086508722 creator A5028120474 @default.
• W2086508722 creator A5046476485 @default.
• W2086508722 creator A5054026126 @default.
• W2086508722 creator A5058819968 @default.
• W2086508722 creator A5060331724 @default.
• W2086508722 creator A5060477667 @default.
• W2086508722 creator A5063900661 @default.
• W2086508722 creator A5078839211 @default.
• W2086508722 creator A5079038577 @default.
• W2086508722 creator A5082243246 @default.
• W2086508722 creator A5085055470 @default.
• W2086508722 creator A5088901931 @default.
• W2086508722 creator A5089699061 @default.
• W2086508722 date "2014-09-30" @default.
• W2086508722 modified "2023-09-27" @default.
• W2086508722 title "Abstract 5030: Antibody blockade of Semaphorin 4D promotes tumor rejection and improves response to immune checkpoint blockade and chemotherapy" @default.
• W2086508722 doi "https://doi.org/10.1158/1538-7445.am2014-5030" @default.
• W2086508722 hasPublicationYear "2014" @default.
• W2086508722 type Work @default.
• W2086508722 sameAs 2086508722 @default.
• W2086508722 citedByCount "0" @default.
• W2086508722 crossrefType "proceedings-article" @default.
• W2086508722 hasAuthorship W2086508722A5000194661 @default.
• W2086508722 hasAuthorship W2086508722A5001292309 @default.
• W2086508722 hasAuthorship W2086508722A5001835930 @default.
• W2086508722 hasAuthorship W2086508722A5009743534 @default.
• W2086508722 hasAuthorship W2086508722A5017065543 @default.
• W2086508722 hasAuthorship W2086508722A5018161067 @default.
• W2086508722 hasAuthorship W2086508722A5022624265 @default.
• W2086508722 hasAuthorship W2086508722A5028120474 @default.
• W2086508722 hasAuthorship W2086508722A5046476485 @default.
• W2086508722 hasAuthorship W2086508722A5054026126 @default.
• W2086508722 hasAuthorship W2086508722A5058819968 @default.
• W2086508722 hasAuthorship W2086508722A5060331724 @default.
• W2086508722 hasAuthorship W2086508722A5060477667 @default.
• W2086508722 hasAuthorship W2086508722A5063900661 @default.
• W2086508722 hasAuthorship W2086508722A5078839211 @default.
• W2086508722 hasAuthorship W2086508722A5079038577 @default.
• W2086508722 hasAuthorship W2086508722A5082243246 @default.
• W2086508722 hasAuthorship W2086508722A5085055470 @default.
• W2086508722 hasAuthorship W2086508722A5088901931 @default.
• W2086508722 hasAuthorship W2086508722A5089699061 @default.
• W2086508722 hasConcept C121608353 @default.
• W2086508722 hasConcept C126322002 @default.
• W2086508722 hasConcept C203014093 @default.
• W2086508722 hasConcept C2776107976 @default.
• W2086508722 hasConcept C2777701055 @default.
• W2086508722 hasConcept C2779013556 @default.
• W2086508722 hasConcept C2779256057 @default.
• W2086508722 hasConcept C2780851360 @default.
• W2086508722 hasConcept C502942594 @default.
• W2086508722 hasConcept C71924100 @default.
• W2086508722 hasConcept C86803240 @default.
• W2086508722 hasConcept C8891405 @default.
• W2086508722 hasConceptScore W2086508722C121608353 @default.
• W2086508722 hasConceptScore W2086508722C126322002 @default.
• W2086508722 hasConceptScore W2086508722C203014093 @default.
• W2086508722 hasConceptScore W2086508722C2776107976 @default.
• W2086508722 hasConceptScore W2086508722C2777701055 @default.
• W2086508722 hasConceptScore W2086508722C2779013556 @default.
• W2086508722 hasConceptScore W2086508722C2779256057 @default.
• W2086508722 hasConceptScore W2086508722C2780851360 @default.
• W2086508722 hasConceptScore W2086508722C502942594 @default.
• W2086508722 hasConceptScore W2086508722C71924100 @default.
• W2086508722 hasConceptScore W2086508722C86803240 @default.
• W2086508722 hasConceptScore W2086508722C8891405 @default.
• W2086508722 hasLocation W20865087221 @default.
• W2086508722 hasOpenAccess W2086508722 @default.
• W2086508722 hasPrimaryLocation W20865087221 @default.
• W2086508722 hasRelatedWork W1985705994 @default.
• W2086508722 hasRelatedWork W2039242416 @default.
• W2086508722 hasRelatedWork W2314390632 @default.
• W2086508722 hasRelatedWork W2326463673 @default.
• W2086508722 hasRelatedWork W2332703482 @default.
• W2086508722 hasRelatedWork W2396720743 @default.
• W2086508722 hasRelatedWork W2400532621 @default.
• W2086508722 hasRelatedWork W2404283593 @default.
• W2086508722 hasRelatedWork W2496438474 @default.
• W2086508722 hasRelatedWork W2505437245 @default.
• W2086508722 hasRelatedWork W2535500972 @default.
• W2086508722 hasRelatedWork W2548092061 @default.
• W2086508722 hasRelatedWork W2741392634 @default.
• W2086508722 hasRelatedWork W2768332305 @default.
• W2086508722 hasRelatedWork W2810193402 @default.
• W2086508722 hasRelatedWork W2885153663 @default.
• W2086508722 hasRelatedWork W2886190874 @default.
• W2086508722 hasRelatedWork W2887524110 @default.
• W2086508722 hasRelatedWork W2955094798 @default.
• W2086508722 hasRelatedWork W3013531700 @default.
• W2086508722 isParatext "false" @default.
• W2086508722 isRetracted "false" @default.

• next